Vida Ventures (Boston)
Edit

Vida Ventures (Boston)

https://www.vidaventures.com/
Last activity: 22.05.2024
Active
Invests in categories: DevelopmentDrugBioTechMedtechPlatformHealthTechTechnologyPersonalProductCar
Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together we form an independent, bold investment group bound together by a simple word – life. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently manages approximately $295 million.
News
128
Portfolio
34
Persons
8
Mentions
14
Location: United States, Massachusetts, Boston
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Series A; Series B

Portfolio 34

DateNameWebsiteTotal RaisedLocation
13.04.2024Capstan Th...capstantx.com$175MUnited Sta...
13.04.2024InduProinduprotx.com-United Sta...
13.04.2024Peloton Th...pelotontherapeutics.com$40.2M-
03.11.2023Avalyn Pha...avalynpharma.com$210.5MUnited Sta...
22.03.2022Affini-Taffinittx.com$175MUnited Sta...
10.02.2022Alterome T...alterome.com$232MUnited Sta...
01.02.2022Centessa P...centessa.com$250MUnited Kin...
01.02.2022Homology M...homologymedicines.com$187MUnited Sta...
30.11.2021Protego Bi...protegobiopharma.com$51M-
30.11.2021Quanta The...quantatx.com$110.7M-
Show more

Persons 8

DateFirst NameLast NameTitleLinkedInLocation
-RajulJain, M.D.Managing D...-
-AlexLoftis, Ph...Senior Ass...-
-AlexMejiaExecutive ...-
-AliciaDortonaExecutive ...-
-StefanVitorovic,...Co-Founder...-
-AlexShen, Ph.D...Director o...-
-MarkSpringel, ...Senior Ass...-
-CassidyHayesCommunicat...-

News 128

DateTitleDescription
03.04.2024Alterome Therapeutics Raises $132 Million in Series B Financing-
26.03.2024Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure-
20.03.2024Capstan Therapeutics Announces $175M Oversubscribed Series B Financing-
21.02.2024ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis-
16.02.2024Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis-
10.02.2024Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering-
30.01.2024AVROBIO and Tectonic Therapeutic Announce Merger-
04.01.2024Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial-
03.01.2024Aktis Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference-
03.01.2024ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia-
Show more

Mentions in press and media 14

DateTitleDescription
22.03.2022Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations-
04.07.2021Vida Ventures Closes Fund III, At $825MVida Ventures Leadership (from left to right): Rajul Jain, Stefan Vitorovic, Arjun Goyal, Arie Belldegrun, Jean-Philippe Kouakou-Zebouah, Helen S. Kim (Photo: Business Wire) Vida Ventures, a Los Angeles, CA- and Boston, MA-based life scienc...
24.06.2021Andreessen Horowitz gears up for more mega crypto betsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The gender pay gap and your investment strategies From Refinitiv Venture capitalists...
24.06.2021Andreessen Horowitz gears up for more mega crypto betsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Change your marketer experience and unleash growth for your business From Optimizely...
24.06.2021Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations-
01.08.2019Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation-
01.08.2019Vida Ventures Closes Second Life Sciences Fund, at $600MVida Ventures, a Boston, MA-based next-generation life sciences venture capital firm, closed Vida Ventures II, LLC, at $600m. Vida II investors include members of the Vida team, investors from the inaugural fund, top-tier endowments, founda...
18.07.2019Vida Ventures Co-Leads $105 Million Series A Financing for Kronos BioBOSTON--(BUSINESS WIRE)--Vida Ventures, LLC (Vida), a next-generation life sciences venture firm, today announced that it co-led the $105 million Series A financing round for Kronos Bio (Kronos). Vida played a prominent role as a seed inves...
18.07.2019Vida Ventures Co-Leads $105 Million Series A Financing for Kronos Bio-
15.04.2019Chapel Hill-Based AskBio Raises $225 Million From TPG Capital and Vida Ventures-
Show more

Reviews 0

Sign up to leave a review

Sign up Log In